JP2012197278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012197278A5 JP2012197278A5 JP2012091882A JP2012091882A JP2012197278A5 JP 2012197278 A5 JP2012197278 A5 JP 2012197278A5 JP 2012091882 A JP2012091882 A JP 2012091882A JP 2012091882 A JP2012091882 A JP 2012091882A JP 2012197278 A5 JP2012197278 A5 JP 2012197278A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- antigen
- binding portion
- tumor cells
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05011536.9 | 2005-05-27 | ||
| EP05011536A EP1726650A1 (en) | 2005-05-27 | 2005-05-27 | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512701A Division JP5038297B2 (ja) | 2005-05-27 | 2006-03-02 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014017392A Division JP6110321B2 (ja) | 2005-05-27 | 2014-01-31 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012197278A JP2012197278A (ja) | 2012-10-18 |
| JP2012197278A5 true JP2012197278A5 (enExample) | 2013-12-05 |
| JP5524270B2 JP5524270B2 (ja) | 2014-06-18 |
Family
ID=34937022
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512701A Active JP5038297B2 (ja) | 2005-05-27 | 2006-03-02 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
| JP2012091882A Active JP5524270B2 (ja) | 2005-05-27 | 2012-04-13 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
| JP2014017392A Active JP6110321B2 (ja) | 2005-05-27 | 2014-01-31 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
| JP2016063219A Pending JP2016190839A (ja) | 2005-05-27 | 2016-03-28 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512701A Active JP5038297B2 (ja) | 2005-05-27 | 2006-03-02 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014017392A Active JP6110321B2 (ja) | 2005-05-27 | 2014-01-31 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
| JP2016063219A Pending JP2016190839A (ja) | 2005-05-27 | 2016-03-28 | 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8198416B2 (enExample) |
| EP (3) | EP1726650A1 (enExample) |
| JP (4) | JP5038297B2 (enExample) |
| CN (1) | CN101233236B (enExample) |
| AT (1) | ATE505544T1 (enExample) |
| AU (1) | AU2006251445B2 (enExample) |
| CA (1) | CA2609682C (enExample) |
| CY (1) | CY1111409T1 (enExample) |
| DE (1) | DE602006021296D1 (enExample) |
| DK (1) | DK1883698T4 (enExample) |
| ES (1) | ES2362795T5 (enExample) |
| PL (1) | PL1883698T5 (enExample) |
| PT (1) | PT1883698E (enExample) |
| RU (1) | RU2458073C2 (enExample) |
| SI (1) | SI1883698T2 (enExample) |
| WO (1) | WO2006125481A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
| ES2606537T3 (es) | 2001-10-23 | 2017-03-24 | Psma Development Company L.L.C. | Anticuerpos contra PSMA |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| GB0715542D0 (en) * | 2007-08-09 | 2007-09-19 | Imp Innovations Ltd | Methods |
| EA201000903A1 (ru) | 2007-11-30 | 2011-02-28 | Калобиос Фармасьютикалс, Инк. | Антитела к pcrv-антигену pseudomonas aeruginosa |
| EP2281004A4 (en) * | 2008-04-14 | 2012-02-15 | Proscan Rx Pharma Inc | PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS |
| ITTO20080313A1 (it) * | 2008-04-22 | 2009-10-23 | Marco Colombatti | Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi |
| EP2352763B2 (en) | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| BRPI0919841A2 (pt) | 2008-10-01 | 2014-11-18 | Micromet Ag | Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas |
| EP2398504B1 (en) * | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| TWI629357B (zh) * | 2009-10-02 | 2018-07-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種特異性的ＰＳＭＡｘＣＤ３雙特異性單鏈抗體 |
| US8772459B2 (en) * | 2009-12-02 | 2014-07-08 | Imaginab, Inc. | J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| SG194510A1 (en) | 2011-04-22 | 2013-12-30 | Emergent Product Dev Seattle | Prostate-specific membrane antigen binding proteins and related compositionsand methods |
| WO2013155605A1 (en) * | 2012-04-19 | 2013-10-24 | Innovascreen Inc. | Method for predicting a pathophysiological condition in an animal |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| CN108603200B (zh) | 2015-11-23 | 2022-08-19 | 诺华股份有限公司 | 优化的慢病毒转移载体及其用途 |
| JP2019500394A (ja) | 2015-12-30 | 2019-01-10 | ノバルティス アーゲー | 有効性が増強された免疫エフェクター細胞治療 |
| CN105968201A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 针对前列腺特异性膜抗原的单域重链抗体 |
| CN105524171A (zh) * | 2016-02-03 | 2016-04-27 | 中国人民解放军第三军医大学第三附属医院 | 一种针对前列腺特异性膜抗原的纳米抗体 |
| CN105542009A (zh) * | 2016-02-03 | 2016-05-04 | 南昌大学 | 一种针对前列腺特异性膜抗原的单域重链抗体 |
| CN105968202A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 针对前列腺特异性膜抗原胞外区的单域重链抗体 |
| CN105968203A (zh) * | 2016-02-03 | 2016-09-28 | 南昌大学 | 一种抗前列腺特异性膜抗原胞外区的单域重链抗体 |
| CN105504061A (zh) * | 2016-02-03 | 2016-04-20 | 南昌大学 | 针对前列腺特异性膜抗原的纳米抗体 |
| CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| SI3443096T1 (sl) | 2016-04-15 | 2023-07-31 | Novartis Ag | Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev |
| BR112018073739A2 (pt) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
| CN109641046B (zh) | 2016-05-20 | 2023-11-07 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| SG11201900885VA (en) | 2016-08-01 | 2019-02-27 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| JP6812551B2 (ja) * | 2016-11-23 | 2021-01-13 | ハープーン セラピューティクス，インク． | 前立腺特異的膜抗原結合タンパク質 |
| JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス，インク． | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法 |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| US20200048359A1 (en) | 2017-02-28 | 2020-02-13 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| BR112020007576A2 (pt) | 2017-10-18 | 2020-09-24 | Novartis Ag | composições e métodos para degradação de proteína seletiva |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| MX2020004229A (es) | 2017-10-25 | 2020-07-22 | Novartis Ag | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. |
| US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
| JP2021505637A (ja) | 2017-12-12 | 2021-02-18 | マクロジェニクス，インコーポレーテッド | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 |
| JP2021521202A (ja) | 2018-04-13 | 2021-08-26 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 固形腫瘍の治療のための標的化されたアマトキシン複合体 |
| US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019222283A1 (en) | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3587454A1 (en) | 2018-06-27 | 2020-01-01 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| FI3830132T3 (fi) * | 2018-07-31 | 2023-01-13 | Humanisoituja vasta-aineita psma:ta vastaan | |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| ES2982474T3 (es) | 2019-02-15 | 2024-10-16 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos |
| CN110407939B (zh) * | 2019-03-12 | 2023-09-29 | 广东医科大学附属第二医院 | 一种人源化抗psma单链抗体及其应用 |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| EP3842461A1 (en) | 2019-12-23 | 2021-06-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
| WO2021164692A1 (zh) * | 2020-02-18 | 2021-08-26 | 和铂医药(上海)有限责任公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| CN111303288B (zh) * | 2020-03-04 | 2020-12-25 | 和铂医药(苏州)有限公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| MX2023000448A (es) | 2020-07-08 | 2023-04-20 | Lava Therapeutics N V | Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta. |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CN118056008A (zh) | 2021-04-27 | 2024-05-17 | 诺华股份有限公司 | 病毒载体生产系统 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
| CN119735685B (zh) * | 2025-03-04 | 2025-06-13 | 深圳真实生物医药科技有限公司 | 一种靶向前列腺特异性膜抗原的抗体、其抗原结合片段、制备方法及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| ZA94916B (en) * | 1993-02-10 | 1995-08-10 | Unilever Plc | Immobilized proteins with specific binding capacities and their use in processes and products |
| IL126314A (en) * | 1996-03-25 | 2003-07-31 | Northwest Biotherapeutics Inc | Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma) |
| US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| IL131380A0 (en) * | 1997-02-26 | 2001-01-28 | Sankyo Co | The use of a compound for the manufacture of a pharmaceutical preparatin for the treatment or prevention of prostate cancer |
| US6258939B1 (en) * | 1997-03-10 | 2001-07-10 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
| ATE342282T1 (de) * | 1999-07-29 | 2006-11-15 | Medarex Inc | Humane monoklonale antikörper gegen prostata spezifisches membranantigen |
| FR2797743B1 (fr) * | 1999-08-23 | 2003-08-08 | Urogene | Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal |
| JP4619651B2 (ja) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| EP1411983A4 (en) * | 2001-06-26 | 2006-06-21 | Imclone Systems Inc | BISPECIFIC ANTIBODIES BINDING TO VEGF RECEPTORS |
| AU2002305767B2 (en) * | 2001-09-20 | 2008-04-10 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA |
| ES2606537T3 (es) * | 2001-10-23 | 2017-03-24 | Psma Development Company L.L.C. | Anticuerpos contra PSMA |
| CN1652821A (zh) * | 2002-01-28 | 2005-08-10 | 米德列斯公司 | 抗前列腺特异性膜抗原(psma)的人单克隆抗体 |
| JP2004000045A (ja) * | 2002-05-31 | 2004-01-08 | Kyowa Hakko Kogyo Co Ltd | 前立腺特異的膜抗原に対する抗体 |
| US6641899B1 (en) * | 2002-11-05 | 2003-11-04 | International Business Machines Corporation | Nonlithographic method to produce masks by selective reaction, articles produced, and composition for same |
| EP1587837B1 (en) * | 2003-01-28 | 2012-06-13 | Proscan RX Pharma Inc. | Epitope sequences for prostate cancer diagnosis and treatment |
| JP2008526979A (ja) * | 2005-01-14 | 2008-07-24 | サイトジェン コーポレーション | 抗ｐｓｍａ抗体による併用癌治療法 |
| JP2008529556A (ja) * | 2005-02-18 | 2008-08-07 | メダレックス， インク． | 前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体 |
| WO2006089231A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| WO2006110745A2 (en) * | 2005-04-08 | 2006-10-19 | Cytogen Corporation | Conjugated anti-psma antibodies |
| EP1726650A1 (en) * | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| US20070160617A1 (en) * | 2005-06-20 | 2007-07-12 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
-
2005
- 2005-05-27 EP EP05011536A patent/EP1726650A1/en not_active Withdrawn
-
2006
- 2006-03-02 DK DK06707388.2T patent/DK1883698T4/en active
- 2006-03-02 AT AT06707388T patent/ATE505544T1/de active
- 2006-03-02 CA CA2609682A patent/CA2609682C/en active Active
- 2006-03-02 CN CN2006800275807A patent/CN101233236B/zh active Active
- 2006-03-02 AU AU2006251445A patent/AU2006251445B2/en active Active
- 2006-03-02 WO PCT/EP2006/001917 patent/WO2006125481A1/en not_active Ceased
- 2006-03-02 EP EP11151622A patent/EP2363486A1/en not_active Ceased
- 2006-03-02 EP EP06707388.2A patent/EP1883698B2/en active Active
- 2006-03-02 SI SI200630996T patent/SI1883698T2/sl unknown
- 2006-03-02 RU RU2007147596/10A patent/RU2458073C2/ru active
- 2006-03-02 DE DE602006021296T patent/DE602006021296D1/de active Active
- 2006-03-02 PL PL06707388T patent/PL1883698T5/pl unknown
- 2006-03-02 PT PT06707388T patent/PT1883698E/pt unknown
- 2006-03-02 US US11/915,454 patent/US8198416B2/en active Active
- 2006-03-02 JP JP2008512701A patent/JP5038297B2/ja active Active
- 2006-03-02 ES ES06707388.2T patent/ES2362795T5/es active Active
-
2011
- 2011-05-04 CY CY20111100431T patent/CY1111409T1/el unknown
-
2012
- 2012-04-13 JP JP2012091882A patent/JP5524270B2/ja active Active
- 2012-05-08 US US13/466,286 patent/US8632777B2/en active Active
-
2013
- 2013-12-13 US US14/105,808 patent/US9238694B2/en active Active
-
2014
- 2014-01-31 JP JP2014017392A patent/JP6110321B2/ja active Active
-
2016
- 2016-03-28 JP JP2016063219A patent/JP2016190839A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012197278A5 (enExample) | ||
| PH12021551720A1 (en) | Dll3 targeting chimeric antigen receptors and binding agents | |
| CN113316591A (zh) | Cd73抗体及其制备方法和应用 | |
| HK1210620A1 (en) | Multi-specific monoclonal antibodies | |
| WO2014012085A3 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| MY207205A (en) | Cd3 antibody and pharmaceutical use thereof | |
| HK1207398A1 (en) | Cd3 binding polypeptides | |
| HK1199837A1 (en) | Humanized antibodies to inkt | |
| RU2017132160A (ru) | Антитела к pd-l1 и их применение для усиления функции t-клеток | |
| WO2012088247A3 (en) | Anti-c5/c5a/c5adesr antibodies and fragments | |
| EA201491524A1 (ru) | Связывающиеся с эритроцитами терапевтические средства | |
| AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| MX359384B (es) | Conjunto mejorado de anticuerpos bisespecificos. | |
| WO2015092024A3 (en) | Method of engineering multi-input signal sensitive t cell for immunotherapy | |
| NZ720765A (en) | Antibodies and methods of use | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| WO2015054691A8 (en) | Tem8 antibodies and their use | |
| EA201790175A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
| CR20110577A (es) | Proteínas de unión a il-1 | |
| NZ623086A (en) | Therapeutic peptides | |
| CL2014000574A1 (es) | Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. | |
| WO2012047732A3 (en) | Antibody compositions and methods of use | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| EP4253959A3 (en) | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule |